pyrazines has been researched along with Epithelial Ovarian Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P | 1 |
| Cho, HY; Kim, YB; No, JH; Park, WH | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
1 review(s) available for pyrazines and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines | 2021 |
1 trial(s) available for pyrazines and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
1 other study(ies) available for pyrazines and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Checkpoint Kinase 1; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Rad51 Recombinase | 2021 |